DelveInsight Business Research, LLP: Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2% During the Study Period (2019-2032) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
In a population-based, sibling-controlled cohort study Jiangwei Sun and colleagues explore the long-term risk of arrhythmias in patients with inflammatory bowel disease.
Cosmo Pharmaceuticals N.V. / Key word(s): AgreementTermination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma 04.09.2023 / 05:45 GMT/BSTDublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the termination by mutual agreement of the license with Dr..
/PRNewswire/ The "Global Dermatology Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com s offering..
Etrasimod was effective and well tolerated as an induction and maintenance therapy
in patients with moderately to severely active ulcerative colitis. Etrasimod is a
treatment option with a unique combination of attributes that might address the persistent
unmet needs of patients with ulcerative colitis.